A comprehensive document on platform trials is now available
The domain of EU-PEARL’s research, Integrated Research Platforms (IRPs) and platform trials is relatively new and consequently the vocabulary is still work in progress. Hence, the need to develop a common understanding and usage of terminology beyond EU-PEARL.
This new resource intends to break down any potential barriers to communicate with the wider world and to promote the use of a standard terminology across the sphere of platform trials research. The document includes key terms that range from comprehensive definitions of master protocol elements and its different types, to statistical terminology or biomarkers terms.
And the document also delves into the platform trials approach and offers a wide range of materials (beyond terminology) to better understand its relevance and scope. It incorporates:
- a curated and rated set of publications references for platform trials
- a summary of the trials using this innovative methodology
- a description of features used in this type of studies and finally
- operational platform trials experiences that can inform the new paradigm of IRPs that EU-PEARL is building.
For the complete document, please download the EU-PEARL Terminology here (pdf).
About EU-PEARL
EU-PEARL is a strategic partnership between the public and private sectors to shape the future of clinical trials by creating a tested and trusted framework for patient-centric integrated research platform (IRP) trials. Through this platform, novel techniques and treatments developed by multiple companies and organizations, are tested in a platform trial. And, EU-PEARL is also developing the specific IRPs frameworks for platform trials ready to operate in four disease areas still facing high unmet needs: Major Depressive Disorder (MDD), Tuberculosis (TB), Non-Alcoholic Steatohepatitis (NASH) and Neurofibromatosis (NF).
This project is funded by the Innovative Medicines Initiative (IMI), a large, far-reaching public-private partnership integrated by the European Union and the pharmaceutical industry to support research and innovation in life-science.
